Latest Breaking News On - Morphic investor - Page 1 : comparemela.com

-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial.

United statesChris erdmanPraveen tipirneniCanaccord genuityDevelopment program updatesSecurities exchangeMorphic holding incExchange commissionChief executive officerRecent corporate highlightsRobarts histopathology indexModified mayo clinic scoreDigestive disease weekSecond quarterMorphic investorMedical meeting